| Identification | Back Directory | [Name]
1H-Imidazo[4,5-b]pyridine, 1-[[5-[(1R)-1-fluoroethyl]-1,3,4-oxadiazol-2-yl]methyl]-6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl- | [CAS]
2144751-78-8 | [Synonyms]
CTX-712
1H-Imidazo[4,5-b]pyridine, 1-[[5-[(1R)-1-fluoroethyl]-1,3,4-oxadiazol-2-yl]methyl]-6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl- | [Molecular Formula]
C19H17FN8O2 | [MOL File]
2144751-78-8.mol | [Molecular Weight]
408.39 |
| Hazard Information | Back Directory | [Uses]
CTX-712 is an orally effective CLK 2 inhibitor, with an IC50 of 1.4 nM, showing anti-tumor activity[1][2]. | [Biological Activity]
CTX-712 is a potent inhibitor of cdc2-like kinase (CLK). CTX-712 inhibits CLK kinase activity, and thus inhibits cancer survival and cancer cell growth. CTX-712 has the potential for the research of cancer disease (extracted from patent JPWO2017188374A1, compound 286)[1]. | [in vivo]
CTX-712 (6.25-12.5 mg/kg, orally, for two weeks) reduces tumor size and increases survival rates in mice with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [1]. | Animal Model: | Mouse models of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). [1] | | Dosage: | 6.25, 12.5 mg/kg, two weeks | | Administration: | Oral | | Result: | Showed two cases of SRSF2 mutations, P95H and P95L observed with significant dose-dependent effects. P95H reduced tumor volume and improved survival rates in the SRSF2 P95L model. |
| [IC 50]
CLK2: 1.4 nM (IC50) | [storage]
Store at -20°C | [References]
[1]. Fused heterocyclic compounds. Patent JPWO2017188374A1. |
|
| Company Name: |
ChemOrigin Pharm
|
| Tel: |
021-15026428026 15026428026 |
| Website: |
chemorigin.com/ |
|